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Abstract
Background: To Assess the efficacy of nebulised hypertonic saline (HS) (3 %) among children with mild to moderately
severe bronchiolitis.
Methods: Infants aged 6 weeks to 24 months, with a first episode of wheezing and Clinical Severity scores (Arch Dis
Child 67:289-93, 1992) between 1 and 8, were enrolled over 4 months duration. Those with severe disease, co-morbidities,
prior wheezing, recent bronchodilator and steroid use were excluded. Patients were randomized in a double-blind
fashion, to receive two doses of nebulized 3 % HS (Group 1) or 0.9 % normal saline (Group 2) with 1.5 mg of L-Epineprine,
delivered 30 min apart. Parents were contacted at 24 h and 7 days. The principal outcome measure was the mean
change in clinical severity score at the end of 2 h of observation.
Results: A total of 100 infants (mean age 9.6 months, range 2–23 months; 61 % males) were enrolled. Patients in both
groups had mild to moderately severe disease at presentation. On an intention-to-treat basis, the infants in the HS
group had a significant reduction (3.57 ± 1.41) in the mean clinical severity score compared to those in the NS group
(2.26 ± 1.15); [p < 0.001; CI: 0.78–1.82]. More children in the HS group (n = 35/50; 70.0 %) were eligible for ER/OPD
discharge at the end of 2 h than those in the NS group (n = 15/50; 30 %; p < 0.001), and less likely to need a hospital
re-visit (n = 5/50; 10.0 %) in the next 24 h as compared to the NS group (n = 15/50, 30.0 %; p < 0.001). The treatment
was well tolerated, with no adverse effects.
Conclusions: Nebulized 3 % HS is effective, safe and superior to normal saline for outpatient management of infants
with mild to moderately severe viral bronchiolitis in improving Clinical Severity Scores, facilitating early Out-Patient
Department discharge and preventing hospital re-visits and admissions in the 24 h of presentation.
Trial registration: Clinicaltrials.gov NCTID012766821. Registered on January 12, 2011.
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Background
Bronchiolitis is a common, occasionally severe viral infec-
tion of the lower respiratory tract responsible for significant
morbidity and mortality in children under two years of age
[1]. According to World Health Organization bulletin, an
estimated 150 million new cases of clinical pneumonia
(principally Pneumonia and Bronchiolitis) occur annually
[2]; 11–20 million among them requiring hospital admis-
sion. Worldwide, 95 % of all cases occur in developing
countries [2]. Epidemiologic data show that RSV accounts
for about 65 % of hospitalizations due to Bronchiolitis [3].
Multiple studies [4–7] have documented variation in
diagnostic testing, treatment modalities practiced and
their outcomes in Bronchiolitis suggesting a lack of con-
sensus for this common disorder. Likewise, despite the
frequency of this condition, there is no unanimously ac-
cepted evidence driven treatment approach [8, 9]. Besides
supplemental oxygen, fluids and supportive care, treatment
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options include, bronchodilators, epinephrine and cortico-
steroids [9]. Hypertonic saline (3 %) is a new agent that has
been found to be promising in recent studies [10–20]. The
proposed mechanism are by improving mucus rheology, re-
ducing airway wall edema and causing sputum induction
and cough [12]. A recent meta-analysis [10] also showed a
consistent improvement in clinical severity scores and sug-
gested HS may also decrease the length of hospital stay in
Bronchiolitis. However, multiple other studies [8, 13, 21–25]
have shown equivocal results with little or no clinical bene-
fits with the use of hypertonic saline (3, 6 or 7 %). Similary,
there is a paucity of data on comparison of important out-
comes like readiness for discharge, need for repeat hospital
visits and hospitalization rates, which are important reflec-
tors of morbidity and economic burden [10]. In the paucity
of rigorously controlled studies in developing countries
using 3 % HS, lack of a consensus regarding management of
bronchiolitis in our practice and an opportunity to improve
care for this common disorder this study was conducted
to assess the therapeutic efficacy of 3 % HS. We tried to
study primarily the improvement in CS scores but also
looked at parameters like readiness for discharge, need for
hospital revisit rates and hospitalization which would
reflect the morbidity and financial burden of disease.
Methods
Trial design
This study was a prospective, interventional, double-
blind randomized controlled trial.
Ethical clearance
A written informed consent was obtained from the pri-
mary caretaker of the patients prior to the enrollment.
The study was approved by the Department of Research,
Institutional Review Board and Ethics Committee of
Tribhuvan University Teaching Hospital.
Study participants
Subjects were recruited from previously healthy children
visiting the Emergency Room (ER) and Out-Patient
Department (OPD) of Kanti Children Hospital with the
following inclusion criteria:
1. Age between 6 weeks and 2 years
2. First Episode of Wheezing
3. Meets Clinical Definition of Bronchiolitis
4. Clinical severity (CS) scores (Wang et al [26])
between 1 and 9 (Table 1).
Bronchiolitis was clinically defined as per the AAP con-
sensus guidelines [4, 27] as the first episode of acute
wheezing in children less than two years of age, starting as
a viral upper respiratory infection (coryza, cough or fever).
Exclusion criteria
1. Any underlying disease (e.g., cystic fibrosis,
bronchopulmonary dysplasia and cardiac or renal
disease),
2. Prior history of wheezing,
3. Diagnosed case of asthma,
4. Oxygen saturation (SpO2) <85 % on room air,
5. CS score > 9,
6. Progressive respiratory distress requiring mechanical
ventilation,
7. Previous treatment with bronchodilators within last
4 h, and
8. Any steroid therapy within 48 h
Study setting
The study was carried out in the ER, Observation room
(OR) and OPD. Recruitment occurred at the peak of
bronchiolitis season in between January 15th to April
15th for duration of 4 months.
Patient assessment
Patient enrollment occurred on weekdays between 08.00
and 17.00 h. The investigator assessed the children for
eligibility and assigned a clinical severity (CS) score de-
scribed by Wang et al. [26] (Table 1). Data were collected
using standardized forms to document pertinent history
and physical exam. Each children’s weight, temperature,
respiratory rate, SpO2 in room air (determined by pulse
oximeter, Siemens), heart rate, CS Score and hydration
status were recorded. The children were stabilized with
antipyretics if necessary (temperature > 38.3*C) and/or
nasal suction if the nose was blocked. Supplemental oxy-
gen by face mask was provided to maintain SpO2 > 90 %.
Table 1 Wang et al. clinical severity score
Variables Score
0 1 2 3
RR < 30 31–45 46–60 > 60
Wheezing None Terminal expiration/only
with stethoscope




Retraction None Intercostals Tracheo-sternal Severe with nasal flaring
General condition Normal Irritable, lethargic, poor feeding
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Patients determined to be in life threatening condition
were immediately managed for same and were not further
considered for study.
Interventions
The study drugs were prepared by a pharmacist, admin-
istered by an ER/OPD nurse and compliance with medi-
cation administration was assured by the investigator’s
direct observation of each nebulization.
All eligible patients were randomly assigned to one of
the two groups:
1. Group 1 (n = 50) received inhalation of L-Epinephrine
1.5 mg, diluted to 4 ml with 3 % Hypertonic 1 Saline
(HS) solution;
2. Group 2 (n = 50) received inhalation of L-Epinephrine,
1.5 mg, diluted to 4 ml with 0.9 % Normal Saline
solution.
The study drug was administered at 0 and 30 min by a
Jet nebulizer using a face mask. The investigator assessed
the children’s general condition and recorded the CS
score, SpO2, RR and HR prior to each drug administration
and at 30, 60 and 120 min after the first nebulization.
The study design is shown in Fig. 1.
Adverse events were defined as heart rate > 200,
tremor and worsening clinical status. Patients were ex-
cluded from the study if the two courses of nebulisation
was not delivered, the drug delivery was delayed by
10 min or more (protocol deviation) or if clinical deteri-
oration mandated escalation of therapy and/or support.
The investigator contacted the parents via telephone 24 h
after their ED/OPD discharge to determine the need for
any unscheduled hospital visit and hospitalization within
the next 24 h of OPD/ ER visit: their readmission (relapse)
rate. The register at the ER/OR was checked daily for any
unscheduled visits by the caretakers. They were also con-
tacted at the end of 1 week in order to record any unsched-
uled medical visits, missed working days of caregivers and
persistence of cough. Patients were labeled as Lost-to-
Follow up if there was failure to communicate for 3 con-
secutive attempts for 2 consecutive days at their 7th and
8th day of initial presentation to the OPD/ER.
Primary outcome
Compare the mean change in Clinical Severity score
among patients with bronchiolitis treated with either
L-Epinephrine- 3 % Hypertonic saline or L-Epinephrine-
0.9 % saline.
Secondary outcomes
a. Assess the improvements in SpO2, respiratory rate
and heart rate in both intervention groups.
b. Compare the discharge readiness and readmission
rates in both intervention groups at the end of 2 h
of observation and within 24 h following discharge
respectively.
c. Describe the socioeconomic burden of illness.
Sample size
Sample size was determined by the following formula:
N ¼ ½ z1 þ z2ð Þ2 ðO12 þ O22Þ  = u^1 – u^2
 
2 :
 N: Sample Size
 z1: The confidence level, for p value: 0.05, z1: 1.96.
 z2: 0.84 for Power of 80 %
1.28 for Power of 90 %
1.64 for Power of 95 %
 Ó1: Standard Deviation of the Outcome Variable
(Clinical Severity Score) in the 1st intervention
group (HS)
 Ó2: Standard deviation of the outcome variable
(Clinical severity score) in the 2nd intervention
group (NS)
 Û 1: Mean change in clinical severity score among
1st intervention group (HS)
Fig. 1 The study design
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 Û 2: Mean change in clinical severity score among
2nd intervention group (NS)
 Allowing a Type1 error of 5 % (α: 0.05), z1 score: 1.96.
 For a Power of 95 %, z2 = 1.64.
The standard deviation of the change in CS score is de-
rived from previous studies [8] and taken as 1.3. We pro-
posed that a difference of 1 point in the CS score between
the two intervention groups will be considered clinically
significant. To detect this mean difference of 1 unit in the
CS score, with a power of 95 %, a sample size of 44 in each
intervention group was required. This required a total of
88 patients to be enrolled in the study. Considering the
drop out/lost to follow up to be approximately 10 %, 100
patients were enrolled, allowing 50 in each group.
Randomization
Sequence generation
A Random Allocation Software [28] generated by com-
puter, identified patients by a triple digit mixed numeric
code, was used by the study coordinator to allocate
patients to treatment groups, and he was the only per-
son with access to the randomization.
Type of randomization
Block Randomization method was used to stratify patients
into blocks of 10 each, each comprising of 10 patients.
Allocation concealment
After preparation, the study solutions were labeled with
the codes and wrapped in an envelope bearing the
Fig. 2 The trial profile
Table 2 Baseline characteristics of 2 groups
Characteristics; mean(SD); (range) Intervention Intervention p value
L-Epi + 3 % HS (n = 50) L-Epi + 0.9 % NS (n = 50)
Age (months), mean (SD); (range) 9.82 (5.06); (2–23) 9.51 (4.28); (3–22) 0.74
Males, n(%) 27 (54.0 %) 21 (42.0 %) 0.40
Duration of illness (days), Mean ± SD 3.43 ± 1.02 3.33 ± 0.96 0.64
Mean (SD) respiratory rate (range) 49.1 (2.5) (46–60) 49.0 (2.0) (46–58) 0.79
Mean (SD) heart rate (range) 148.7 (7.5) (132–168) 149.7 (7.1) (132–166) 0.49
Mean (SD) Spo2 (range) 93.4 (0.8) (90–95) 93.5 (0.7) (90–94) 0.69
Mean (SD) clinical severity score (range) 5.3 (1.6) (3–9) 5.2 (1.1) (3–9) 0.57
Mean temperature (SD) temperature (*C) (range) 37.2 (−17.4) (36.7–38.0) 37.3 (−17.4) (36.6–38.0) 0.82
Urine specific gravity 1016 1022 0.001
ER enrollment, n (%) 2 (4 %) 2 (4 %) 1.00
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respective codes. Study solutions were identical in ap-
pearance and odor. Their identity was blinded to all
participants, care providers, and investigators and out-
come assessor.
Implementation
Randomization was done by the study coordinator (not
involved in the study), who was the only person to have
access to the codes. The codes were a mixed 3 digit nu-
meric code. The study solutions prepared by a pharmacist
(not involved in the study) were stored in the non-freezer
compartment (2–8*C) of the refrigerator and discarded if
not used within 72 h of preparation. The investigator
assessed the patients and allocated the treatment modal-
ities to each one of them himself.
Blinding
The study was a Double Blind Randomized Controlled
Trial with the investigator, the participants, the nurses
who delivered the drug being blinded to the thera-
peutic option.
Statistical methods
Statistical analysis was performed using SPSS for Windows,
Release 16.0 (SPSS Inc., Chicago, IL). Dichotomous events
were analyzed by using the Chi-Square test. Continuous
variables were compared by Student t-test. Statistical sig-
nificance was defined as p-value < 0.05. This trial has been
reported in accordance to the Consolidated Standards of
Reporting Trials (CONSORT, 2010) guidelines [29].
Results and discussion
A total of 754 children were screened and 146 previously
well children were assessed for eligibility in the study
periodas shown in Fig. 2. Forty-Six children were
Table 3 Distribution of risk factors proposed to contribute to
prolonged disease course and, or severity in both intervention
groups
Variables 3 % HS + L-Epi 0.9 % NS + L-Epi p-value
(n = 50) (n = 50)
Family history of asthma,
n (%)
4 (8.0) 5 (10.0) 1.00
Parental smoking, n (%) 30 (60.0) 21 (42.0) 0.05
Exposure to biofuels, n (%) 14 (28.0) 8 (16.0) 0.11
Breastfeeding status, n (%) 48 (96.0) 48 (96.0) 0.75
Prematurity, n (%) 3 (6.0) 2 (4.0) 0.50
Atopic history, n (%) 7 (14.0) 3 (6.0) 0.15
Table 4 Mean (± SD) for CS Score, respiratory rate, heart rate and SpO2 for patients in each group at 0,30, 60 and 120 min of
assessment
Intervention
0.9 % NS + L-Epi
(n = 50)
Intervention
3 % HS + L-Epi
(n = 50)
p value 95 % confidence interval lower
limits – upper limits (mean)
CS score, n, Mean ± S.D; range
0 min 5.2 ± 1.1 (3–9) 5.3 ± 1.6; (3–9) 0.57 −0.73; 0.41 (−0.15)
30 min 4.9 ± 1.1; (3–8) 4.3 ± 2.0; (2–8) 0.10 −0.11; 1.21 (0.55)
60 min 3.2 ± 1.0; (1–6) 2.2 ± 1.2; (1–7) 0.001 0.52; 1.43 (0.97)
120 min 2.9 ± 0.8; (1–5) 1.7 ± 0.9; (1–7) 0.001 0.77; 1.52 (1.14)
Respiratory rate, breaths/minute, Mean ± S.D; range
0 min 49.0 ± 2.0; (46–58) 49.1 ± 2.5; (46–60) 0.79 −1.01;0.81 (−0.12)
30 min 47.4 ± 1.7; (46–54) 46.6 ± 2.1; (42–56) 0.04 0.04; 1.61 (0.81)
60 min 45.3 ± 1.4; (42–50) 43.5 ± 2.0; (40–52) 0.001 1.13; 2.57 (1.85)
120 min 43.6 ± 2.6; (40–48) 40.7 ± 2.0; (38–49) 0.001 1.97; 3.86 (2.91)
Oxygen saturation,%, Mean ± S.D; range
0 min 93.5 ± 0.7; (90–94) 93.4 ± 0.8 (90–95) 0.69 −0.22; 0.40 (0.09)
30 min 93.8 ± 0.8; (91–96) 94.2 ± 1.2; (90–96) 0.07 −0.79; 0.06 (−0.36)
60 min 94.9 ± 0.9; (92–97) 95.8 ± 1.1; (92–98) 0.001 −1.34; −0.48 (−0.97)
120 min 95.6 ± 1.0; (93–98) 97.0 ± 1.0; (93–99) 0.001 −1.77; −0.91 (−1.14)
Heart rate, beats/minute, Mean ± S.D; range
0 min 149.7 ± 7.1; (132–166) 148.7 ± 7.5; (132–168) 0.49 −1.94; 3.98 (0.80)
30 min 149.7 ± 7.9; (130–164) 147.1 ± 9.1; (130–164) 0.13 −0.93; 6.04 (2.91)
60 min 145.2 ± 6.4; (130–156) 142.6 ± 7.2; (126–156) 0.06 −0.20; 5.30 (2.55)
120 min 141.8 ± 5.8; (126–154) 138.3 ± 6.6; (124–152) 0.006 1.02; 6.03 (3.53)
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excluded and 99 patients completed the study. Data was
analyzed on an intention to treat basis.
No significant differences were noted between the study
groups with respect to baseline characteristics (p > 0.05)
and risk factors for severity as shown in Table 2 and
Table 3 respectively. Patients in both groups had moder-
ately severe bronchiolitis with mean CS score above 5.
There is gradual improvement in CS score with time in
both the groups and the effect seemed to be more pro-
nounced after the second session of nebulisation at
60 min. Patients who received nebulised HS had more sig-
nificant improvement in the baseline CS scores (Group 1,
a change of 3.57 ± 1.41; Group 2, a change of 2.26 ± 1.15;
p < 0.01) at the end of 2 h of therapy as shown in Table 5.
There was also significant difference in the mean change
in CS scores, HR, RR and SpO2 between the two groups
at the start of treatment and at the end of 2 h of therapy
(p <0.001) as shown in Table 4 and Table 5. More infants
who received HS were eligible for discharge at the end of
2 h as compared to NS [Group 1, n = 35(71.0 %); Group 2,
n = 15(30.0 %); p < 0.001] as shown in Table 6.
In addition, in our trial the need for repeat medical visits
and hospital admission within the next 24 h of initial hos-
pital visit (Relapse rate) was 20 %, which was significantly
lesser in the babies who received HS compared to those
who received NS [Group 1, n = 5(10.0 %); Group 2, n = 15
(30.0 %); p < 0.001] as shown in Table 6. During the subse-
quent week, 78 out of 100 patients (Group 1, n = 37;
Group 2, n = 41) were accessible. As shown in Table 7, a
large number of patients in both groups had persistent
cough at the end of 1 week (Group 1, n = 31; Group 2,
n = 37; p = 0.45). Eighteen patients from HS Group and
23 patients from NS Group had at least 1 unscheduled
medical visit within 1 week (p = 0.58; overall revisit
rates 41/88; 46.5 %) and 3 parents from HS Group and
10 patients from NS Group reported at missing least
1 day of work (p = 0.17; total missed days of work 10/
77; 12.9 %). No adverse events occurred in either treat-
ment groups. No children were withdrawn from the
trial due to side effects or clinical deterioration.
Ours is one of the few studies conducted in South-
East Asia with a rigorously controlled design that has
not only tried to look at the role of hypertonic saline in
improving the CS scores but also studied its impact on
early discharge eligibility and hospital revisit rates. In
both treatment groups, change in CS was greater than
2 scores suggesting that both treatment combinations
were effective. More infants with bronchiolitis were
eligible for early discharge and less likely to need any
hospital re-visit within the next 24 h (p < 0.001). This
outcome seems to be particularly relevant in planning
resource allocation and staffing in treatment of this
common condition.
Similar findings were reported in a recent Cochrane
review [10] by Zhang et al., where a total of 560 patients
treated with nebulised 3 % saline had a significantly
shorter mean length of hospital stay and significantly
lower post-inhalation clinical score than the 0.9 % saline
group in the first three days of treatment (p < 0.001).
The effects of improving clinical score were observed in
both outpatients and inpatients.
On the Contrary, in another double blind RCT, Wu
et al. in 2014 [24] assessed the role of nebulised 3 % HS
on change in RDAI scores, admission rates and length of
stay in Bronchiolitis. They concluded that HS given to
children in the ED decreases hospital admissions but did
not produce any significant difference in Respiratory
Distress Assessment Instrument score or length of stay
as compared to NS.
Likewise, Florin et al. [22] conducted a RCT in ER
setting and found that at 1 h after the intervention, the
Table 5 Clinical outcomes in the two intervention groups at




3 % HS + L-Epi
Intervention
0.9 % NS+ L-Epi




3.57 ± 1.41 2.26 ± 1.15 0.001 0.78; 1.82 (1.30)
Change
in HR
10.38 ± 4.54 7.87 ± 3.63 0.003 0.86; 4.16 (2.50)
Change
in RR
8.44 ± 2.15 5.40 ± 2.57 0.001 2.08; 3.99 (3.04)
Change
in SpO2
3.53 ± 0.84 2.12 ± 0.80 0.001 1.07; 1.73 (1.30)
Table 6 Secondary outcomes







after 120 mins, n (%)
35 (70.0 %) 15 (30.0 %) 0.001
Relapse rate, n (%) 5 (10.0 %) 15 (30.0 %) 0.02
Need for intensive care 1 (2.0 %) 1 (2.0 %) 1.00








1 week, n (%)
18 (36.0 %) 23 (46.0 %) 0.58
Missed days of work 3 (6.0 %) 10 (20.0 %) 0.17
Persistence of cough
at the end of 1 week,
n (%)
31 (62.0 %) 37 (74.0 %) 0.37
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HS group demonstrated significantly less improvement
in the median RDAI Score compared with the NS
group (p < 0.001) and hence concluded that nebulised
3 % Saline was not effective in improving RDAI scores
in the ER setting.
Previously, Sarrell et al. [19] had shown that substitut-
ing hypertonic saline for normal saline solution (2 ml) in
the inhalation mixture for delivering bronchodilator im-
proved clinical scores and decreased hospitalization rates
in ambulatory children. In hospitalized children with
more severe bronchiolitis, nebulized 4 ml hypertonic
saline solution with or without epinephrine was found to
be more effective treatment. In our study all infants re-
covered in both the groups, there was no treatment fail-
ure or significant adverse events following nebulisation,
as previously reported by Ralston et al. [30].
Our study was well designed to minimize the common
bias and limitations associated with research. Sampling
bias was addressed by block randomization of patients.
Blinding was maintained throughout the study period. A
single observer’s assessments nullified the chances of
inter-observer variability. Despite these measures, some
amount of bias and attrition is inevitable. We could not
clarify the additional benefits of supportive care alone in
infants with bronchiolitis since we didn’t have a placebo
arm. Although we considered important outcomes such
as hospital revisit and admission rates, we did not assess
the impact of therapy on the length of hospital stay. Our
study population consisted mainly of infants who pre-
sented earlier, had mostly mild symptoms and experi-
enced significant benefits. We are unsure, if similar
benefits could be reproduced in infants with a more se-
vere disease presentation. Although, we had strict inclu-
sion and exclusion criteria, and identified potential risk
factors for asthma, we might have included infants with
first episode of asthma. RSV testing was unavailable and
hence not done. We are also unsure if co-infection
worsens the outlook in our infants.
Our study was conducted at the largest tertiary level
pediatric referral centre of our country with over 1000
ER visits per month and more than 10,000 OPD visits
per month with seasonal variation. Our sampled popula-
tion characteristics were truly representative of the gen-
eral population visiting Kanti Children’s Hospital. Strict
inclusion and exclusion criteria were used to minimize
possible confounding effects of uncharacterized and
evolving wheezing phenotypes. A well defined objective,
previously validated scoring system was used to assess
the clinical response. Our adequate sample size, and
double blinded design minimizes the common bias and
limitations associated with research. Since our study
only consisted of mild to moderate patients with Bron-
chiolitis, results may need caution while extrapolating to
infants with severe disease.
Conclusion
Nebulised 3 % hypertonic saline in combination with epi-
nephrine was effective in reducing the Clinical Severity
scores, meeting the eligibility criteria for OPD/ER dis-
charge and reducing the need for hospital admission
among ambulatory children with bronchiolitis. We believe
this simple, inexpensive, safe, and effective treatment inter-
vention could minimize the morbidity of Bronchiolitis by
generalizing its use in centers caring for pediatric patients.
Similar study could be done in multicentric settings with a
larger sample size, involving more severely affected pa-
tients, and with a placebo control design in order to con-
firm and extend our results.
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